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ABSTRACT
Objective To evaluate the acceptability and safety 
profile of nocturnal long- term oxygen therapy (LTOT) 
in children with sickle cell disease (SCD) and chronic 
hypoxaemia.
Design Retrospective cohort study.
Patients, setting and intervention Children with 
SCD who started LTOT from 2014 to early 2019 in two 
tertiary hospitals in London, UK were retrospectively 
enrolled. Patients who started disease- modifying 
therapies <12 months before LTOT or while on LTOT were 
excluded.
Main outcome measures Minor and major adverse 
events during LTOT were reported. Laboratory and clinical 
data, transcranial Doppler (TCD) scans and overnight 
oximetry studies performed at steady state within 12 
months before and after starting LTOT were compared.
Results Nineteen children (10 males; median age 
12 years, range 6–15) were included. Nearly half of 
them (9/19; 47%) were on hydroxyurea at baseline. No 
child discontinued LTOT because of intolerance or poor 
adherence. No major adverse events were reported. 
Laboratory data did not show significant changes in 
haemoglobin and reticulocyte count after 1 year of 
follow- up. No statistically significant change in the 
incidence of vaso- occlusive pain events was noted 
(median annual rate from 0.5 to 0 episode per patient/
year; p=0.062). Overnight oximetry tests performed 
while on LTOT showed improvements in all oxygen 
saturation parameters (mean overnight and nadir SpO2, 
% of time spent with SpO2 <90%) compared with the 
baseline.
Conclusion LTOT is a safe and feasible treatment 
option for children with SCD and chronic hypoxaemia.
INTRODUCTION
Sickle cell disease (SCD) is a hereditary blood 
disease with multi- organ involvement.1 This condi-
tion affects millions of people, especially in sub- 
Saharan Africa, but its burden is also increasing 
in many western countries, in part because of the 
impact of recent migration.2
In patients with SCD, deoxygenated haemo-
globin S (HbS) tends to polymerise damaging the 
red- cell membrane and making red blood cells 
(RBCs) rigid and sickle- shaped, causing intravas-
cular haemolysis.3 In such conditions, RBCs tend 
to adhere to leucocytes and vascular endothelium, 
impairing capillary blood flow and causing vaso- 
occlusion, which in turn triggers tissue ischaemia.4 
Repeated cycles of ischaemia, reperfusion and intra-
vascular haemolysis induce oxidant stress and more 
inflammation that, along with other factors, cause 
chronic vasculopathy.5 Overall, these mechanisms 
deriving from oxygen desaturation are the main 
contributors to both acute and chronic manifesta-
tions of SCD and chronic hypoxaemia might there-
fore be expected to significantly exacerbate them.
The prevalence of hypoxaemia is high in chil-
dren with SCD, with almost half of them showing 
nocturnal oxygen desaturation6 and over a third 
low daytime oxygen saturation (SpO2) at steady 
state.7 Moreover, chronic hypoxaemia has been 
associated with an increased risk of cerebrovascular 
disease,8 9 left ventricular dysfunction10 and pulmo-
nary hypertension,11 even in young patients.
Limited evidence is available on safety or efficacy 
of long- term oxygen therapy (LTOT) for chronic 
hypoxaemia in patients with SCD. Few small case 
series12–14 have reported that continuous high- flow 
oxygen therapy is harmful as it suppresses erythro-
poietic drive with a subsequent fall in haemoglobin 
concentration and an increase in the incidence of 
painful vaso- occlusive pain events (VOEs).12 13 One 
of these was an adult case report,13 while in the other 
two12 14 neither ages of the patients nor the degree 
of chronic hypoxaemia was reported. In two of 
these studies, oxygen was provided at much higher 
levels than current norms.12 14 On the contrary, Ip et 
al observed no detrimental effects on erythropoiesis 
and painful crises with the use of nocturnal low- 
flow LTOT in six adult patients with SCD.15 Recent 
What is already known on this topic?
 ► Chronic hypoxaemia is a common complication 
of sickle cell disease in children and it can affect 
clinical outcomes. Previous small case series 
have reported that continuous oxygen therapy 
is harmful as it suppresses erythropoietic 
drive with a subsequent fall in haemoglobin 
concentration and an increase in the incidence 
of painful crises. This has led to a reluctance 
to use home oxygen therapy, but its long- term 
safety is not known.
What this study adds?
 ► This is the first study to show that the use of 
low- flow nocturnal long- term oxygen therapy 
is a safe and well- tolerated treatment option 
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American Thoracic Society guidelines based on very low- quality 
evidence offered conditional recommendation to use LTOT in 
children with SCD and severe chronic hypoxaemia, defined as 
a SpO2 <90% (1) for at least 5% of recording time of a contin-
uous monitoring (eg, overnight oximetry) or (2) at least in three 
separate spot pulse oximetry checks.16 In summary, small case 
series have noted possible negative effects of continuous high- 
flow oxygen therapy due to the risk of suppression of erythro-
poiesis and rebound VOEs after withdrawal.12–14 17 This has led 
to a reluctance to use LTOT.
This is the first study that aimed to assess the acceptability and 
safety profile of nocturnal LTOT in a cohort of children with 
SCD and chronic hypoxaemia. We also described the impact of 
this intervention on SpO2 parameters and clinical outcomes after 
1 year of follow- up.
METHODS
This retrospective observational study was performed for quality 
improvement purposes. Clinical records of paediatric patients 
with SCD at two different tertiary hospitals (Evelina London 
Children’s Hospital and King’s College Hospital, London, UK) 
who started LTOT between January 2014 and January 2019 
were retrospectively reviewed. Inclusion criteria for patients 
with SCD (HbSS or HbS/β0 thalassaemia) were the indication for 
starting LTOT obtainable from medical charts and the absence 
of missing values in the baseline and follow- up laboratory, clin-
ical history data, transcranial Doppler (TCD) results and over-
night oximetry studies. Patients who had concurrent CPAP with 
O2 treatment, hydroxyurea (HU) or any other disease- modifying 
therapy (ie, chronic transfusion, experimental drugs) started 
within the year preceding LTOT and while on LTOT, as well as 
those who underwent tonsillectomy and adenoidectomy (T&A) 
surgery during the study period, were excluded.
Home oxygen was administered via nasal cannula or mask 
according to the patient’s preference, at the rate of 0.5–2 L/min, 
through the use of an oxygen concentrator (online supplemen-
tary appendix 1). Nasal cannulae/masks were replaced every 1 or 
2 weeks. Home caregivers were given appropriate education and 
training about the management of the equipment. Patients on 
nocturnal oxygen had regular follow- up appointments with the 
paediatric haematologists and/or paediatric pulmonologist every 
3–6 months and underwent also periodical follow- up nocturnal 
oximetry.
Assessments
For daytime SpO2, overnight oximetry, TCD and laboratory 
data, in each participant the closest record to the beginning of 
LTOT and the latest (up to 14 months for TCD scans and blood 
tests) after starting it were compared.
A Nonin GO2 pulse oximeter (Nonin, Plymouth, MN, USA) 
was used to measure daytime SpO2, with the value recorded 
after at least 2 min of stable SpO2 readings and a clear pulsatile 
photoplethysmographic signal.
Nocturnal oximetry tests (Bitmos GmbH, Masimo sat 801+) 
were carried out over one night at the sleep laboratory of the 
Evelina London Children’s Hospital, within 1 year before and 
after starting LTOT. During nocturnal oximetry, parents kept a 
sleep diary. Artefacts due to poor perfusion, low signal identifi-
cation and movement were manually excluded, as were periods 
of wakefulness according to the sleep diary’s records. Studies 
with less than 4 hours of artefact- free data were excluded. Anal-
ysis software provided standard parameters, including overnight 
mean and nadir SpO2. Oxygen flow rate was initially set at 0.5 L/
min in all patients, and then progressively titrated to have SpO2 
between 94% and 97% (online supplementary appendix 1).
Patients with reported symptoms of sleep- disordered breathing 
(eg, loud snoring, witnessed apnoeas, restless sleep and mouth 
breathing) also underwent a cardiorespiratory sleep study at 
baseline (SOMNOtouch device; SOMNOmedics, Germany) to 
evaluate the presence of obstructive sleep apnoea. Hypercapnia 
was evaluated through nocturnal capnography at baseline (TCM 
4/40 monitoring system; Radiometer).18
Clinical and laboratory data
Information on participants’ demographics and medical history 
was taken from medical records. A history of asthma was defined 
according to the evidence of a physician’s diagnosis of asthma 
from medical records. A VOE was identified as an episode of 
acute pain that lasted at least 4 hours for which there was no 
explanation other than vaso- occlusion and that required hospital 
admission with administration of parenteral analgesics.19 The 
annual rate of VOEs was defined as the average number of events 
per patient/year requiring hospital admission and was calculated 
for the year preceding and following the beginning of LTOT.
TCD imaging was used in all examinations, following strict 
protocols.18 The transducer orientation was optimised at every 
2 mm interval in each vessel to ensure that the highest, audible 
Doppler frequency signal was obtained. The highest time aver-
aged mean of the maximum velocity (TAMMV) measured in 
selected arteries were used for comparisons.18
Laboratory data at steady state, performed on the same day of 
TCD scans, before and after initiating LTOT were collected (Hb, 
reticulocyte count, white blood cell count, neutrophil count, 
platelet count, lactate dehydrogenase (LDH), aspartate amino-
transferase (AST) total bilirubin and % fetal Hb).
Statistical analysis
Statistical analyses were performed using GraphPad Prism 
V.7.04 for Windows (GraphPad Software, La Jolla, CA, USA, 
www. graphpad. com). Continuous variables were expressed as 
mean (SD) or median (IQR 25th−75th). All variables were anal-
ysed for normality distribution (D’Agostino- Pearson omnibus 
normality test). Differences between groups were evaluated 
either by Wilcoxon matched- pairs signed- rank test and paired 
t- test as appropriate. Fisher’s exact test was used to compare 
frequencies and percentages. A p value ≤0.05 was considered 
statistically significant.
RESULTS
Twenty- six children and adolescents with SCD were commenced 
on LTOT between 2014 and 2019. Of these, seven patients were 
excluded for not matching inclusion criteria (figure 1), leaving 
19 HbSS subjects (10 boys, 53%, median age when starting 
LTOT 12 years; range 6–15) in the final study population.
Nine out of nineteen patients (47%) were on HU at base-
line, having started this therapy a median time of 2 years before 
(range, 1–6 years). Eleven children (58%) had a previous history 
of asthma. No child suspended LTOT during study period, 
except for one who discontinued after 10 months in light of 
marked improvements at overnight oximetry. Complete baseline 
clinical and demographic characteristics of our cohort are shown 
in table 1. Baseline cardiorespiratory sleep study results were 
available in 13 out of 19 patients (68%). Of these, 11 patients 
had an apnoea/hypopnea index (AHI) <1, whereas the other 
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Children were commenced on a median 0.5 L/min of supple-
mental oxygen (range, 0.2–2 L/min). Minor adverse effects 
related to the use of LTOT were reported in 4/19 children 
(21%), who complained of intolerance for nasal prongs or nasal 
dryness at some point of the follow- up period. No major adverse 
event was observed.
Blood test results and VOEs
Reported blood test results were performed at steady state at 
a median time interval of 5.5 (range 1–10) months before and 
9.5 (range 5–14) months after starting home oxygen (table 2). 
Hb level and reticulocyte count were not affected, while signif-
icant decreases were shown in mean LDH (from 994±473 
to 756±329 U/L; p=0.001) and AST values (from 61±19 to 
52±12 U/L; p=0.012) after initiating LTOT (table 2).
Moreover, after 1 year of LTOT, the median annual rate of 
VOEs requiring hospitalisation did not significantly change 
(from 0.5 (IQR 0–2) to 0 episode per patient/year (IQR 0–0); 
p=0.062) (figure 2).
Nocturnal oximetry
All patients underwent an overnight oximetry at baseline 
(range, 0–3 months before LTOT) and while on oxygen therapy 
(range, 9–12 months after starting LTOT). Nocturnal oximetry 
results comparing baseline tests off- oxygen and follow- up tests 
on oxygen supplementation are shown in table 3. Children on 
LTOT showed a significant increase of median overnight and 
nadir SpO2 (p<0.001 and p<0.001, respectively), as well as 
a marked reduction of per cent time spent with SpO2 <90% 
(p<0.001) (table 3). The proportion of children with at least 
5% of time of nocturnal SpO2 monitoring <90% passed from 
79% (15/19) at baseline to 16% (3/19, p<0.001) with the inter-
vention, while the number of children with spot daytime SpO2 
<90% decreased from 3 to 1.
Figure 1 Figure 1Study population. CPAP, continuous positive airway 
pressure; HU, hydroxyurea; LTOT, long- term nocturnal home oxygen 
therapy; SCD, sickle cell disease.
Table 1 Baseline characteristics of 19 patients with SCD who 
started nocturnal home oxygen
Variable n (%)
N. of patients 19
Males 10 (53%)
Median age at starting home oxygen (IQR 
25th−75th)
12.0 years (7.5–13.0)
Hb type—SS 19 (100%)
HU treatment at baseline 9 (47%)
Previous surgery for T&A 10 (53%)
Chronic asthma 11 (58%)
Nocturnal enuresis 6 (31%)
Indication to start home oxygen:
  ≥5% of time continuous SpO2 monitoring 
<90% alone*
12 (63%)
  ≥5% of time continuous SpO2 monitoring 
<90% AND daily spot SpO2 <90%*
3 (16%)
  At least three daily spots† SpO2 <93% 
AND concerns about severity of SCD- related 
manifestation
4 (21%)
*Consistently with the criteria indicated for SCD paediatric patients by the American 
Thoracic Society Guidelines for home oxygen therapy in children.16
†On three different occasions.
Hb, haemoglobin; HU, hydroxyurea; SCD, sickle cell disease; T&A, tonsillectomy and 
adenoidectomy.
Table 2 Effect of long- term nocturnal oxygen therapy (LTOT) on 





Hb g/L 76±9 77±9 0.471*
Ret ×109/L 305±103 278±93 0.323†
HbF % 5.9±3.7 5±2.9 0.104*
WBC ×103/L 11.9±3 11.4±3.3 0.400†
N ×103/L 5.9±2.9 4.9±2.6 0.143
PLT ×106/L 374±96 381±143 0.721†
LDH U/L 994±473 756±329 0.001*
AST U/L 61±19 52±12 0.012†
Total bilirubin μmol/L 62±24 62±42 0.371*
*Wilcoxon matched- pairs signed- rank test.
†Paired t- test.
AST, aspartate aminotransferase; Hb, haemoglobin; HbF, fetal haemoglobin; LDH, 
lactate dehydrogenase; N, neutrophil count; PLT, platelet count; Ret, reticulocyte 
count; SCD, sickle cell disease; WBC, white blood cell count.
Figure 2 Number of vaso- occlusive pain episodes (VOEs) in 19 
children with sickle cell disease in the 12 months before and after 
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Transcranial Doppler
TCD scans were recorded at a median time interval of 5.5 
(range, 1–10) months before and 9.5 (range, 5–14) months 
after starting home oxygen. Significant decreases in right middle 
cerebral artery (from 127±16 to 119±20 cm/s; p=0.034), 
right posterior cerebral artery (from 84±18 to 72±16 cm/s; 
p=0.042) and right distal internal carotid artery (from 113±38 
to 97±23 cm/s; p=0.039) TAMMV were recorded after starting 
LTOT. No significant differences were shown for other velocities 
(online supplemental table 1).
DISCUSSION
This is the first study to show that the use of nocturnal LTOT is 
a safe and well- tolerated treatment option in children with SCD 
and chronic hypoxaemia, with only a few minor adverse effects 
reported.
Two previously published case series raised concerns regarding 
erythropoiesis suppression when administering continuous high- 
flow oxygen for several days in patients with SCD.12 14 On a 
pathophysiology perspective, oxygen supplementation might 
inhibit the hypoxia- inducible transcriptor factors, which increase 
the production of erythropoietin in kidney and liver and enhance 
erythroid progenitor maturation and proliferation in the bone 
marrow.20 However, a previous study showed that erythropoi-
etin levels remained stable in non- hypoxic adults randomised to 
receive oxygen during a painful crisis.21 In our study popula-
tion, there was some decrease of reticulocyte levels with LTOT, 
although it was not significant and it did not affect Hb concentra-
tion. Similarly, a retrospective observational study of six adults 
with SCD undergoing LTOT at 1–2 L/min did not show any 
detrimental effect on erythropoiesis at a 6- month follow- up,15 
and a randomised crossover trial comparing 1- week nocturnal 
auto- adjusting CPAP versus nocturnal home oxygen therapy in 
children and adults with SCD did not report significant changes 
in Hb level with home oxygen.22 These findings suggest that, 
when using nocturnal LTOT at low- flow oxygen rates, compen-
satory mechanisms neutralise the negative impact of oxygen 
supplementation on erythropoiesis, resulting in a preservation 
of baseline Hb levels in patients with SCD.
Supplementary oxygen therapy may theoretically increase 
oxidative stress as well, as largely demonstrated in subjects 
treated with hyperbaric oxygen therapy.23 However, SCD is 
intrinsically linked to multiple sources of pro- oxidant processes 
with consequent chronic and systemic oxidative stress. Due to 
the complex pathophysiology of these processes, it would be 
difficult to disentangle the oxidative stress due to LTOT from 
that triggered by other causes.24–26
We documented only a few minor adverse effects in children 
with SCD undergoing nocturnal LTOT (ie, dry nose or throat, 
noise disrupting sleep), whereas there were no serious adverse 
event related to this intervention. Although we were not able to 
document the daily adherence to nocturnal LTOT in our cohort, 
there were no cases of premature suspension of the intervention 
for patients’ refusal.
Our data showed that oxygen supplementation improved 
overnight oxygen saturation in patients with SCD. We hypoth-
esised that this could result in decreased rates of HbS polymer-
isation that could have a positive impact on vasculopathy and 
clinical outcomes, as suggested by the improvement of some 
TCD parameters and spot daytime SpO2 values. Larger prospec-
tive studies are needed to prove this hypothesis. We noted no 
statistically significant changes in the incidence of VOEs or in 
the variation of haemoglobin concentration, and this further 
supports the safety of LTOT in children with SCD. In previous 
case series, rebound painful crisis on interruption of oxygen 
therapy was noted,12 while other studies did not demonstrate 
any effect.21 27 28 Therefore, despite our encouraging preliminary 
findings, the evaluation of the impact of LTOT on VOE inci-
dence warrants further and more robust confirmation in larger 
prospective studies. Encouragingly, our results also suggested 
that LTOT might lead to reduced haemolysis, with reduced LDH 
and AST levels, which could potentially offer long- term benefits.
Strength and limitations
All the children were assessed in a highly specialised hospital 
setting before starting nocturnal LTOT; therefore, we could 
extract detailed and reliable baseline data from hospital software. 
The exclusion of patients who started disease- modifying drugs 
over the course of the study period limited the confounding effect 
of HU on oxygen saturation clinical outcomes.29 30 However, the 
dose of HU and adherence to this therapy, which might have 
affected the outcomes, were not documented through the study. 
Among the other limitations, the retrospective design of the 
study prevented us from performing an advanced stratified anal-
ysis according to age or other baseline factors. However, due to 
the complete lack of evidence regarding the safety of LTOT in 
children with SCD, this design could be considered acceptable. 
It was not possible to formally measure the day- by- day adher-
ence to nocturnal LTOT, but few complaints and an overall good 
adherence were reported during follow- up visits. Follow- up was 
limited to 12 months after starting LTOT, which prevented us 
from evaluating long- term clinical outcomes and side effects. 
Finally, this study was not designed to establish whether the posi-
tive effects of LTOT on oxygen saturation and clinical outcomes 
persist when the intervention is stopped.
Future directions
Beneficial effects of LTOT in terms of VOEs and haemolysis 
need to be confirmed in larger prospective studies with longer 
follow- up. Such studies should also evaluate which are the 
subgroups of patients with SCD and chronic hypoxaemia that 
Table 3 Effect of long- term nocturnal home oxygen therapy (LTOT) on overnight oximetry of children with sickle cell disease
Baseline*
Median (IQR 25th–75th)
1 year after LTOT†
Median (IQR 25th–75th)
P value
(Wilcoxon matched- pairs signed- rank test)
Daily SpO2 % 92 (91.5–92.5) 95 (93–95) <0.001
Mean overnight SpO2 % 91 (89.5–92) 95 (93–96) <0.001
Nadir overnight SpO2% 81 (79–84.5) 87 (85–90) <0.001
% time SpO2 <90% 12.3 (4.7–56) 0.8 (0–2.4) <0.001
*Oximetry studies recorded off oxygen supplementation.
†Oximetry studies recorded while on oxygen supplementation.
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are most likely to benefit from LTOT according to baseline char-
acteristics and duration/modalities of intervention.
Conclusions
In conclusion, over 12 months, LTOT was shown to be a safe 
and feasible intervention in children with SCD and chronic 
hypoxaemia, with some possible beneficial clinical effects.
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